Epirubicin (Brand name: Ellence)
~~~~~~~~~~~~~~~~~~~~~
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
Background: The addition of anthracyclines to platinum-based chemotherapy may provide benefit in survival in ovarian cancer patients.
We evaluated the effect on survival of adding epirubicin to standard carboplatin and paclitaxel.
Conclusion: The addition of epirubicin to standard carboplatin and paclitaxel treatment did not improve survival in patients with advanced
ovarian, tubal or peritoneal cancer.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.